×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KZIA – kazia therapeutics limited - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KZIA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
8/5
10:01 am
kzia
Kazia Therapeutics surges 53% on positive data from phase 1 trial of brain cancer drug [Seeking Alpha]
High
Report
Kazia Therapeutics surges 53% on positive data from phase 1 trial of brain cancer drug [Seeking Alpha]
8/5
08:46 am
kzia
KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
High
Report
KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
8/5
08:40 am
kzia
KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
High
Report
KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
8/2
08:36 am
kzia
Kazia Therapeutics Limited (NASDAQ: KZIA) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating.
Low
Report
Kazia Therapeutics Limited (NASDAQ: KZIA) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating.
8/2
07:46 am
kzia
Kazia Therapeutics Limited (NASDAQ: KZIA) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
Low
Report
Kazia Therapeutics Limited (NASDAQ: KZIA) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
7/12
08:15 am
kzia
KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER
Low
Report
KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER
7/6
07:00 am
kzia
US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
Medium
Report
US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
6/17
10:45 am
kzia
Thinking about buying stock in Electric Last Mile Solutions, Advent Technologies, Cisco Systems, Kazia Therapeutics, or Comcast?
Medium
Report
Thinking about buying stock in Electric Last Mile Solutions, Advent Technologies, Cisco Systems, Kazia Therapeutics, or Comcast?
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
8/5
08:19 am
kzia
Form 6-K KAZIA THERAPEUTICS LTD For: Aug 05
Medium
Report
Form 6-K KAZIA THERAPEUTICS LTD For: Aug 05
8/1
08:52 am
kzia
Form 6-K KAZIA THERAPEUTICS LTD For: Aug 01
High
Report
Form 6-K KAZIA THERAPEUTICS LTD For: Aug 01
7/6
06:05 am
kzia
Form 6-K KAZIA THERAPEUTICS LTD For: Jul 06
Low
Report
Form 6-K KAZIA THERAPEUTICS LTD For: Jul 06
6/30
06:06 am
kzia
Form 6-K KAZIA THERAPEUTICS LTD For: Jun 30
Low
Report
Form 6-K KAZIA THERAPEUTICS LTD For: Jun 30
6/23
07:40 am
kzia
Form 6-K KAZIA THERAPEUTICS LTD For: Jun 23
Low
Report
Form 6-K KAZIA THERAPEUTICS LTD For: Jun 23
6/17
04:55 pm
kzia
Form 6-K KAZIA THERAPEUTICS LTD For: Jun 17
Medium
Report
Form 6-K KAZIA THERAPEUTICS LTD For: Jun 17
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/27
Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock.
1.4%
4/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.5%
12/26 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.6%
1/7 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.1%
2/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.9%
6/23 Edison issues ADR outlook on Kazia Therapeutics (KZIA) 3.1%
2/10 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.2%
8/20 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.7%
4/29 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.0%
5/8 New positive data from phase IIa trial in brain cancer patients 12.8%
4/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.5%
12/26 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.6%
1/7 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.1%
2/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.9%
6/23 Edison issues ADR outlook on Kazia Therapeutics (KZIA) 3.1%
2/10 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.2%
8/20 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.7%
4/29 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.0%
5/8 New positive data from phase IIa trial in brain cancer patients 12.8%
TOP News Decliners
1/24
Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating.
-2.4%
1/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -2.9%
12/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
12/2 Edison issues ADR outlook on Kazia Therapeutics (KZIA) -6.7%
11/25 Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference -7.4%
4/8 Kazia Therapeutics up 18% premarket on positive paxalisib data [Seeking Alpha] -8.0%
7/17 Kazia calls for greater awareness of the deadliest brain cancer in the US -8.4%
5/8 Kazia calls for greater awareness of the deadliest gynecological cancer in the US -8.5%
11/19 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.6%
11/20 Kazia Therapeutics up 83% [Seeking Alpha] -18.9%
1/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -2.9%
12/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
12/2 Edison issues ADR outlook on Kazia Therapeutics (KZIA) -6.7%
11/25 Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference -7.4%
4/8 Kazia Therapeutics up 18% premarket on positive paxalisib data [Seeking Alpha] -8.0%
7/17 Kazia calls for greater awareness of the deadliest brain cancer in the US -8.4%
5/8 Kazia calls for greater awareness of the deadliest gynecological cancer in the US -8.5%
11/19 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.6%
11/20 Kazia Therapeutics up 83% [Seeking Alpha] -18.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: